Related Experiment Video
Updated: Mar 2, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular
Anna Bochicchio1,2,3, Sandra Jordaan4, Valeria Losasso5
1German Research School for Simulation Sciences, Forschungszentrum Jülich, Jülich 52425, Germany. a.bochicchio@fz-juelich.de.
Abstract:
Targeted human cytolytic fusion proteins (hCFPs) are humanized immunotoxins for selective treatment of different diseases including cancer. They are composed of a ligand specifically binding to target cells genetically linked to a human apoptosis-inducing enzyme. hCFPs target cancer cells via an antibody or derivative (scFv) specifically binding to e.g., tumor associated antigens (TAAs). After internalization and translocation of the enzyme from endocytosed endosomes, the human enzymes introduced into the cytosol are efficiently inducing apoptosis. Under in vivo conditions such enzymes are subject to tight regulation by native inhibitors in order to prevent inappropriate induction of cell death in healthy cells. Tumor cells are known to upregulate these inhibitors as a survival mechanism resulting in escape of malignant cells from elimination by immune effector cells. Cytosolic inhibitors of Granzyme B and Angiogenin (Serpin P9 and RNH1, respectively), reduce the efficacy of hCFPs with these enzymes as effector domains, requiring detrimentally high doses in order to saturate inhibitor binding and rescue cytolytic activity. Variants of Granzyme B and Angiogenin might feature reduced affinity for their respective inhibitors, while retaining or even enhancing their catalytic activity. A powerful tool to design hCFPs mutants with improved potency is given by in silico methods. These include molecular dynamics (MD) simulations and enhanced sampling methods (ESM). MD and ESM allow predicting the enzyme-protein inhibitor binding stability and the associated conformational changes, provided that structural information is available. Such "high-resolution" detailed description enables the elucidation of interaction domains and the identification of sites where particular point mutations may modify those interactions. This review discusses recent advances in the use of MD and ESM for hCFP development from the viewpoints of scientists involved in both fields.
Insights
Targeted human cytolytic fusion proteins (hCFPs) show promise for cancer treatment but are hindered by natural inhibitors. In silico methods like molecular dynamics (MD) and enhanced sampling methods (ESM) are advancing hCFP design by predicting inhibitor binding and guiding mutations for improved efficacy.
Area of Science:
- Biochemistry
- Molecular Biology
- Computational Biology
Background:
- Targeted human cytolytic fusion proteins (hCFPs) are engineered immunotoxins for selective disease treatment, particularly cancer.
- hCFPs utilize a targeting ligand and a human apoptosis-inducing enzyme to eliminate diseased cells after internalization.
- Cancer cells can evade hCFPs by upregulating native inhibitors (Serpin P9, RNH1) that neutralize effector enzymes like Granzyme B and Angiogenin.
Purpose of the Study:
- To explore the use of in silico methods, specifically molecular dynamics (MD) and enhanced sampling methods (ESM), for designing more potent hCFPs.
- To investigate how to overcome inhibitor-mediated resistance in hCFPs by designing enzyme variants with reduced inhibitor affinity.
- To leverage computational approaches for identifying specific mutations that enhance hCFP efficacy.
Main Methods:
- Molecular dynamics (MD) simulations to predict enzyme-inhibitor binding stability.
- Enhanced sampling methods (ESM) to analyze conformational changes and binding interactions.
- In silico design of hCFP mutants with potentially altered inhibitor binding affinities.
Main Results:
- MD and ESM provide high-resolution insights into enzyme-inhibitor interactions.
- These computational tools can identify specific interaction domains and mutation sites to modify binding.
- The approach facilitates the rational design of hCFP variants with improved potency against cancer cells.
Conclusions:
- In silico methods like MD and ESM are powerful tools for advancing hCFP development.
- These methods enable the design of hCFPs that overcome inhibitor resistance, leading to more effective cancer therapies.
- Further integration of computational and experimental approaches will accelerate the creation of next-generation hCFPs.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

